Xcout IntelSign inSubscribe

Anteris Technologies Global Corp. competitors & alternatives

AVRMedical DevicesEagan, United States

The 12 closest competitors and alternatives to Anteris Technologies Global Corp. among medical devices companies — ranked by similarity to what Anteris Technologies Global Corp. actually does, not by market-cap band.

$658.3MMarket cap
174Employees
12Competitors listed

Subscribe to see Anteris Technologies Global Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

Anteris Technologies Global Corp. at a glance

Anteris Technologies Global Corp. is a medical devices company headquartered in Eagan, United States. It is publicly listed (AVR) with a market capitalisation of $658.3M. Xcout tracks 24 named people at Anteris Technologies Global Corp., including Wayne Geoffrey Paterson (Vice Chairman & Chief Executive Officer). Xcout recorded 61 job postings from Anteris Technologies Global Corp. in the last 90 days.

Anteris Technologies Global Corp. leadership

  • Wayne Geoffrey PatersonVice Chairman & Chief Executive Officer
  • Wayne PatersonVice Chairman & CEO
  • David DenisPresident & Director
  • Denis David StPresident & Director
  • Brent A. MoenChief Financial Officer
  • Matthew McDonnellChief Financial Officer

18 more named people on record for Anteris Technologies Global Corp., with roles, board committees and tenure — see the full roster →

Hiring at Anteris Technologies Global Corp.

Xcout recorded 61 job postings from Anteris Technologies Global Corp. in the last 90 days, from a hiring record Xcout has kept since June 2026.

The weekly hiring trend, the roles and locations behind it — see Anteris Technologies Global Corp.'s hiring signals →

Top 12 Anteris Technologies Global Corp. competitors

Ranked by semantic similarity — how close each company is to Anteris Technologies Global Corp. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Artivion, Inc.AORT · Medical DevicesKennesaw, United States
69% matchPublic

Similar medical devices company

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Market cap$1.4B
Employees1,600
Artivion, Inc. competitors & alternatives →
Edwards LifesciencesEW · Medical - DevicesIrvine, United States
67% matchPublic

Medical - Devices

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Market cap$52.7B
Employees16,000
Python
Edwards Lifesciences competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Anteris Technologies Global Corp. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Anteris Technologies Global Corp.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →